Flamingo Therapeutics
0 followers
Flamingo is pioneering RNA-targeted therapies for oncology with state-of-the art chemistries and a clinical-stage pipeline targeting undruggable transcription factors and splice variants. Flamingo Therapeutics has a Phase II trial (PEMDA-HN) evaluating the STAT3 targeting agent danvatirsen, in comb... Read more
Org chart
Stephane van Rooijen
Chief Executive Officer
Stephane van Rooijen
Collapse
Andrew Denker
Chief Medical Officer
Susan MacIntyre
Vice President Clinical Operations
Mark Gidjunis
VP Finance - Corporate Controller
Floor Stam
Co-founder, VP Of Corporate Development And Operations
